A primary focus is on overcoming therapeutic resistance, particularly in colorectal cancer, where the initial failure of single-agent BRAF inhibitors led to the discovery that feedback activation of EGFR reactivates the pathway [156]. The gene discussed is BRAF; the disease is colorectal cancer.